Stephan J Sanders, Mustafa Sahin, Joseph Hostyk, Audrey Thurm, Sebastien Jacquemont, Paul Avillach, Elise Douard, Christa L Martin, Meera E Modi, Andres Moreno-De-Luca, Armin Raznahan, Alan Anticevic, Ricardo Dolmetsch, Guoping Feng, Daniel H Geschwind, David C Glahn, David B Goldstein, David H Ledbetter, Jennifer G Mulle, Sergiu P Pasca, Rodney Samaco, Jonathan Sebat, Anne Pariser, Thomas Lehner, Raquel E Gur, Carrie E Bearden
De novo and inherited rare genetic disorders (RGDs) are a major cause of human morbidity, frequently involving neuropsychiatric symptoms. Recent advances in genomic technologies and data sharing have revolutionized the identification and diagnosis of RGDs, presenting an opportunity to elucidate the mechanisms underlying neuropsychiatric disorders by investigating the pathophysiology of high-penetrance genetic risk factors. Here we seek out the best path forward for achieving these goals. We think future research will require consistent approaches across multiple RGDs and developmental stages, involving both the characterization of shared neuropsychiatric dimensions in humans and the identification of neurobiological commonalities in model systems...
October 2019: Nature Medicine